COHA logo
Home / COHA News / Novel Triple Therapy in Murine Models and Spontaneous Canine Malignancies Provides Hope for Clinical Translation to Humans

Novel Triple Therapy in Murine Models and Spontaneous Canine Malignancies Provides Hope for Clinical Translation to Humans

Davis examined the efficacy and immunologic effects of a novel triple therapy consisting of local radiotherapy, intratumoral CpG oligodeoxynucleotides (CpG ODN), and systemic indolamine-2,3-dioxygenase (IDO) blockade in mouse models and dog clinical trials.

A team of medical and veterinary researchers at the University of California – Davis examined the efficacy and immunologic effects of a novel triple therapy consisting of local radiotherapy, intratumoral CpG oligodeoxynucleotides (CpG ODN), and systemic indolamine-2,3-dioxygenase (IDO) blockade in mouse models and dog clinical trials. The addition of IDO blockage to radiotherapy + CpG decreased IDO activity, reduced tumor growth and reduced immunosuppressive factors.

INVESTIGATORS

  • Arta Monjazeb, MD, PhD
  • Michael Kent, DVM, PhD

THREE KEY BENEFITS TO THE FINDINGS

Results suggested that IDO maintains immune suppression in tumors after therapy and IDO blockade promotes a local anti-tumor immune response with systemic consequences
Demonstrated that combinatorial strategies designed to minimize overlapping toxicity can be safe and effective
Results provided strong rationale for clinical translation of the triple-therapy strategy to substantially improve the already documented efficacy of radiotherapy + CpG

LINKS

What Dogs Teach Us About Cancer
Blocking indolamine-2,3-dioxygenase rebound immune suppression boosts antitumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies